Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Receivables (2020 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Receivables for 6 consecutive years, with $100000.0 as the latest value for Q3 2025.

  • For Q3 2025, Receivables rose 127.27% year-over-year to $100000.0; the TTM value through Sep 2025 reached $100000.0, up 127.27%, while the annual FY2024 figure was $556000.0, N/A changed from the prior year.
  • Receivables hit $100000.0 in Q3 2025 for Cyclerion Therapeutics, down from $525000.0 in the prior quarter.
  • Across five years, Receivables topped out at $581000.0 in Q1 2025 and bottomed at $44000.0 in Q3 2024.
  • Average Receivables over 5 years is $244750.0, with a median of $192500.0 recorded in 2021.
  • Year-over-year, Receivables crashed 57.71% in 2023 and then soared 127.27% in 2025.
  • Cyclerion Therapeutics' Receivables stood at $100000.0 in 2021, then decreased by 4.0% to $96000.0 in 2022, then changed by 0.0% to $96000.0 in 2023, then skyrocketed by 479.17% to $556000.0 in 2024, then tumbled by 82.01% to $100000.0 in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $100000.0, $525000.0, and $581000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.